Gemini Therapeutics, Inc. (NASDAQ:GMTX) Shares Sold by Ergoteles LLC

Ergoteles LLC lowered its position in shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Rating) by 13.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 92,200 shares of the company’s stock after selling 13,900 shares during the period. Ergoteles LLC owned about 0.21% of Gemini Therapeutics worth $151,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. increased its position in shares of Gemini Therapeutics by 3.5% during the first quarter. BlackRock Inc. now owns 1,300,204 shares of the company’s stock worth $1,807,000 after purchasing an additional 43,831 shares in the last quarter. Millennium Management LLC increased its position in shares of Gemini Therapeutics by 42.1% during the second quarter. Millennium Management LLC now owns 762,163 shares of the company’s stock worth $1,288,000 after purchasing an additional 225,961 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Gemini Therapeutics by 2,850.4% during the first quarter. Renaissance Technologies LLC now owns 351,100 shares of the company’s stock worth $488,000 after purchasing an additional 339,200 shares in the last quarter. Nantahala Capital Management LLC acquired a new stake in shares of Gemini Therapeutics during the third quarter worth about $423,000. Finally, Bank of Montreal Can acquired a new position in Gemini Therapeutics in the 2nd quarter valued at about $276,000. Institutional investors and hedge funds own 75.42% of the company’s stock.

Gemini Therapeutics Trading Down 0.9 %

Gemini Therapeutics stock opened at $24.50 on Wednesday. The stock has a 50 day moving average of $21.20 and a two-hundred day moving average of $8.51. Gemini Therapeutics, Inc. has a twelve month low of $1.16 and a twelve month high of $14.10. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -24.50 and a beta of -0.12.

About Gemini Therapeutics

(Get Rating)

Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.